Skip to main content
. 2021 Mar 21;11(3):567. doi: 10.3390/diagnostics11030567

Figure 2.

Figure 2

Incremental costs and health benefits of strategies compared to the status quo. Incremental costs and health benefits are per 1000 children initiating ART over a 10-year time horizon. No incremental cost-effectiveness ratio (ICER) was calculated for pretreatment drug resistance (PDR) testing because it was dominated by improved switching (PDR testing gained fewer life years (LYs) at a greater cost compared to improved switching).